| You
are here: Home: BCU 2|2003: Charles
L Vogel, MD, FACP: Select publications
Select publications
Trastuzumab: 2002 San Antonio Breast Cancer Symposium
update
Carey LA et al. Response to trastuzumab (Herceptin) given
with paclitaxel (taxol, T) immediately following 4AC as initial
therapy for primary breast cancer (BrCa). Breast Cancer
Res Treat 2002; Abstract
424.
Chan A et al. Clinical efficacy & toxicity of Herceptin
in metastatic breast cancer patients with tumours that overexpress
Her-2 neu: The Australian expanded access program. Breast
Cancer Res Treat 2002; Abstract
444.
Chan A et al. Multinational phase II study of navelbine
(N) and herceptin (H) as first-line therapy for HER2-overexpressing
metastatic breast cancer (HER2+ MBC). Breast Cancer Res
Treat 2002; Abstract
434.
Dieras V et al. Previous cumulative anthracycline dose
is the main determinant of LVEF decrease in breast cancer patients
treated with trastuzumab (Herceptin®): Results of a French compassionate
use program. Breast Cancer Res Treat 2002; Abstract
425.
Filipovich E et al. Chemotherapy with trastuzumab plus
vinorelbine in patients with erb-B2 overexpressed tumor is active
in metastatic breast cancer. Breast Cancer Res Treat 2002;
Abstract
436.
Gelmon K et al. Efficacy and safety of Herceptin in women
with Her2-positive (HER2+) metastatic breast cancer (MBC) who have
progressed on a prior herceptin-containing regimen. Breast
Cancer Res Treat 2002; Abstract
440.
Janku F et al. Weekly trastuzumab (T) and paclitaxel (P)
in metastatic breast cancer (MBC). The impact of taxane free interval
(TFI) on treatment outcomes. Breast Cancer Res Treat 2002;
Abstract
435.
Lüftner DI et al. Evaluation of serum HER-2/neu for
outcome assessment and monitoring of Herceptin plus combination
chemotherapy in metastatic breast cancer. Breast Cancer
Res Treat 2002; Abstract
427.
Lüftner DI et al. Longitudinal HER-2/neu measurements
during treatment with Herceptin, epirubicin plus cyclophosphamide
(HEC): Interim serum results of a phase II study in patients with
metastatic breast cancer. Breast Cancer Res Treat 2002;
Abstract
423.
Miller KD et al. Phase II study of gemcitabine, paclitaxel
and trastuzumab in metastatic breast cancer: A Hoosier Oncology
Group trial. Breast Cancer Res Treat 2002; Abstract
437.
Pichon MF et al. Serum HER-2/neu extracellular domain
parallels responses to trastuzumab treatment of recurrent breast
cancer. Breast Cancer Res Treat 2002; Abstract
426.
Raab G et al. Multicenter randomized phase II study of
docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first
line therapy for HER2 overexpressing adjuvant anthracyclin pretreated
metastatic breast cancer (MBC). Breast Cancer Res Treat
2002; Abstract
443.
Robert N et al. Phase III comparative study of trastuzumab
and paclitaxel with and without carboplatin in patients with HER-2/neu
positive advanced breast cancer. Breast Cancer Res Treat
2002; Abstract
35.
Thomssen CH et al. Cardiac safety of epirubicin/cyclophosphamide
(EC) alone and in combination with herceptin in women with metastatic
breast cancer (MBC). Breast Cancer Res Treat 2002; Abstract
430.
Van Pelt AE et al. Phase II study of neoadjuvant trastuzumab
plus docetaxel for locally advanced and metastatic breast cancer
that overexpresses HER2/neu: A preliminary report. Breast
Cancer Res Treat 2002;
Abstract 441.
Yardley DA et al. Final results of the Minnie Pearl Cancer
Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab
in metastatic breast cancer. Breast Cancer Res Treat 2002;
Abstract
439.
Clinical trials involving the combination of vinorelbine and
capecitabine
Ahn Sr, JH et al. Phase II study of combination chemotherapy
of capecitabine and vinorelbine in metastatic breast cancer with
previous exposure to anthracycline and taxane: Preliminary results.
Proc ASCO 2002; Abstract
2030.
Domenech G et al. Vinorelbine/capecitabine (VINOCAP) combination
remission induction therapy for metastatic breast cancer (MBC).
Proc ASCO 2001; Abstract
1939.
Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine
(vinocap) as front line chemotherapy in metastatic breast cancer
(MBC). Proc ASCO 2002; Abstract
1978.
Hess DD et al. Phase I-II trial of capecitabine and vinorelbine
in elderly patients (pts: > 65y) with metastatic breast cancer
(MBC): SAKK 25/99 for the Swiss Group of Clinical Cancer Research,
Berne, Switzerland. Proc ASCO 2002;
Abstract 2915.
Schott AF et al. Vinorelbine (VR) and capecitabine (CAP)
in metastatic breast cancer: Phase I/II study with correlative genotype,
phenotype, and pharmacokinetics. Breast Cancer Res Treat
2002; Abstract
338.
Von Minckwitz G et al. In-vivo-chemosensitivity adapted
preoperative chemotherapy (PCT) in patients (P) with primary operable
breast cancer. First experiences of the pilot GEPARTRIO - study.
Breast Cancer Res Treat 2002; Abstract
156.
Welt A et al. Phase I study of capecitabine and vinorelbine
in pretreated patients with metastatic breast cancer. Proc
ASCO 2001;
Abstract 1979.
Welt A et al. Extended phase I study of capecitabine in
combination with vinorelbine in pretreated patients with metastatic
breast cancer. Breast Cancer Res Treat 2002; Abstract
336.
|
